David Shaw’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

David Shaw’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$757K	Buy	11,416 +1,180	+12%	+$69.1K	﹤0.01%	3943
2026 Q1	$554K	Buy	+10,236	New	+$571K	﹤0.01%	3800
2025 Q2	–	Sell	-7,737	Closed	-$339K	–	4781
2025 Q1	$339K	Sell	7,737 -700	-8%	-$30.9K	﹤0.01%	3711
2024 Q4	$363K	Buy	8,437 +1,899	+29%	+$86.3K	﹤0.01%	3794
2024 Q3	$290K	Buy	+6,538	New	+$280K	﹤0.01%	3992
2020 Q2	–	Sell	-16,900	Closed	-$610K	–	4294
2020 Q1	$610K	Hold	16,900	–	–	﹤0.01%	3097
2019 Q4	$772K	Hold	16,900	–	–	﹤0.01%	3156
2019 Q3	$601K	Hold	16,900	–	–	﹤0.01%	3123
2019 Q2	$673K	Buy	+16,900	New	+$665K	﹤0.01%	2912

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

David Shaw's XPH Position: Q2 2026 in Review

David Shaw increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 12% in Q2 2026, buying an estimated $69.1K and bringing the position to 11,416 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

David Shaw first reported a position in XPH in Q2 2019 and has held it in 9 quarters since. The position peaked at $772K in Q4 2019. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

David Shaw held 11,416 shares of State Street SPDR S&P Pharmaceuticals ETF worth $757K as of Q2 2026.
David Shaw bought 1,180 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $69.1K.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3943 holding.
David Shaw first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2019 and has held it in 9 quarters since.
David Shaw's State Street SPDR S&P Pharmaceuticals ETF position peaked at $772K in Q4 2019.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.